Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma
Keisuke Watanabe(University of Pennsylvania), Carl H. June(Parker Institute for Cancer Immunotherapy), Paul Haun(University of Pennsylvania), Sangya Agarwal(Amgen (United States)), Angela M. Gomez(University of Pennsylvania), Mikko Siurala(Parker Institute for Cancer Immunotherapy), Decheng Song(University of Pennsylvania), Antonia Rotolo(University of Pennsylvania), Alain H. Rook(The Wistar Institute), Regina M. Young(University of Pennsylvania), Avery D. Posey(Parker Institute for Cancer Immunotherapy), Marco Ruella(University of Pennsylvania), John Scholler(University of Pennsylvania), Tong Da(University of Pennsylvania), Shunichiro Kuramitsu(University of Pennsylvania)
Cited by 43
Related Papers
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|792
Cytotoxic T Cells in Cytomegalovirus Infection
|New England Journal of Medicine|1982|596
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
|JCI Insight|2018|573
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554